Stocks · News reference
DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 61.29 percent increase over losses of $(0.31) per share from
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 YearsThe BLA is supported by the results from the successful Phase 3 VITESSE trial –
DBV Technologies announced the submission of a Biologics License Application (BLA) to the FDA for its VIASKIN® Peanut patch, designed to treat peanut allergies in children aged 4-7 years. The application is based on positive results from the Phase 3 VITESSE clinical trial, the largest immunotherapy study conducted in this patient population, involving 654 children. DBV has requested priority review of the BLA.
DBV Technologies submitted a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch, a non-invasive epicutaneous immunotherapy treatment for peanut allergies in children aged 4-7 years. The submission is supported by positive results from the VITESSE Phase 3 clinical trial involving 654 children, the largest immunotherapy trial for this population. DBV has requested Priority Review status.
DBV Technologies announced the sale of approximately $50 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The company had previously filed an ATM prospectus for up to $150 million in sales. As of August 31, 2026, the company had 314,388,807 total shares outstanding.